Comparative Effects of Olmesartan and Azelnidipine on Atrial Structural Remodeling in Spontaneously Hypertensive Rats

被引：6

作者：

Okamura, Kazuki ^{[1
]}

Ito, Masahiro ^{[1
]}

Tanaka, Komei ^{[1
]}

Chinushi, Masaomi ^{[1
]}

Adachi, Takeshi ^{[3
]}

Mitsuma, Wataru ^{[1
]}

Hirono, Satoru ^{[1
]}

Nakazawa, Mikio ^{[2
]}

Kodama, Makoto ^{[1
]}

Aizawa, Yoshifusa ^{[1
]}

机构：

[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Cardiol, Niigata 9518510, Japan

[2] Niigata Univ, Fac Med, Sch Hlth Sci, Dept Med Technol, Niigata 9518510, Japan

[3] Natl Def Med Coll, Dept Internal Med 1, Saitama, Japan

来源：

PHARMACOLOGY | 2009年 / 83卷 / 06期

关键词：

Atrial structural remodeling; Angiotensin 2 type 1 receptor blocker; Oxidative stress; CARDIAC MYOCYTE HYPERTROPHY; CONGESTIVE-HEART-FAILURE; OXIDATIVE STRESS; ANGIOTENSIN-II; FIBRILLATION SUBSTRATE; CARDIOVASCULAR INJURY; NITRIC-OXIDE; INHIBITION; NADPH; SUPEROXIDE;

D O I：

10.1159/000218103

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The differential effects between olmesartan (OM), an angiotensin 2 type 1 receptor blocker (ARB), and azelnidipine (AZ), a calcium channel blocker (CCB), on atrial structural remodeling were studied in spontaneously hypertensive rats (SHR). Eight weeks after treatment, both OM and AZ decreased systolic blood pressure to similar levels. Histological analysis revealed that both OM and AZ had decreased the size of the atrial myocytes and interstitial fibrosis in the atrium, and that the effects of OM were greater than those of AZ. These beneficial effects of OM were associated with less atrial oxidative stress, as assessed by 3-nitrotyrosine staining, and less activation of Rac1, a regulatory component in NADPH oxidase. These results suggest that the ARB was more effective than the CCB in ameliorating atrial structural remodeling due to the suppression of oxidative stress. Copyright (C) 2009 S. Karger AG, Basel

引用

页码：360 / 366

页数：7

共 29 条

[1] S-glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide [J].

Adachi, T ;

Weisbrod, RM ;

Pimentel, DR ;

Ying, J ;

Sharov, VS ;

Schöneich, C ;

Cohen, RA .

NATURE MEDICINE, 2004, 10 (11) :1200-1207

[2] Antioxidant improves smooth muscle sarco/endoplasmic reticulum Ca2+-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation [J].

Adachi, T ;

Matsui, R ;

Xu, SQ ;

Kirber, M ;

Lazar, HL ;

Sharov, VS ;

Schöneich, C ;

Cohen, RA .

CIRCULATION RESEARCH, 2002, 90 (10) :1114-1121

[3] Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways [J].

Cardin, S ;

Li, DS ;

Thorin-Trescases, N ;

Leung, TK ;

Thorin, E ;

Nattel, S .

CARDIOVASCULAR RESEARCH, 2003, 60 (02) :315-325

[4] Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage - Role of the NADPH and xanthine oxidases [J].

Dudley, SC ;

Hoch, NE ;

McCann, LA ;

Honeycutt, C ;

Diamandopoulos, L ;

Fukai, T ;

Harrison, DG ;

Dikalov, SI ;

Langberg, J .

CIRCULATION, 2005, 112 (09) :1266-1273

[5] Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence [J].

Ehrlich, JR ;

Hohnloser, SH ;

Nattel, S .

EUROPEAN HEART JOURNAL, 2006, 27 (05) :512-518

[6] Nonchannel drug targets in atrial fibrillation [J].

Goette, A ;

Lendeckel, U .

PHARMACOLOGY & THERAPEUTICS, 2004, 102 (01) :17-36

[7] Oxidative stress and cardiovascular injury - Part I: Basic mechanisms and in vivo monitoring of ROS [J].

Griendling, KK ;

FitzGerald, GA .

CIRCULATION, 2003, 108 (16) :1912-1916

[8] Oxidative stress and cardiovascular injury - Part II: Animal and human studies [J].

Griendling, KK ;

FitzGerald, GA .

CIRCULATION, 2003, 108 (17) :2034-2040

[9] Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers - A meta-analysis [J].

Healey, JS ;

Baranchuk, A ;

Crystal, E ;

Morillo, CA ;

Garfinkle, M ;

Yusuf, S ;

Connolly, SJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (11) :1832-1839

[10] Atrial fibrillation: Hypertension as a causative agent, risk factor for complications, and potential therapeutic target [J].

Healey, JS ;

Connolly, SJ .

AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (10) :9G-14G

← 1 2 3 →